Cisplatin is a medication used to manage and treat solid tumors and hematologic malignancies. It is in the alkylating agent class of cytotoxic medications.<\/strong> It is used to treat various types of cancers, including sarcomas, some carcinomas (e.g., small cell lung cancer, squamous cell carcinoma of the head and neck and ovarian cancer), lymphomas, bladder cancer, cervical cancer, and germ cell tumors.<\/strong><\/p>\n If CISPLATIN for injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n Note:<\/strong> Cisplatin for injection is a platinum-based drug indicated for the treatment of: \u2022 Advanced testicular cancer \u2022 Advanced ovarian cancer \u2022 Advanced bladder cancer<\/p>\n Approval Date: 1978 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import CISPLATIN for injection\u201d based on the information you provide.<\/p>\nHow can 1 go about obtaining CISPLATIN for injection?<\/h3>\n
CISPLATIN for injection, for intravenous use Initial U.S. Approval: 1978<\/h5>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\nReferences<\/h3>\n
\n
\nSee Drugs@FDA for information about all of CDER\u2019s approved drugs and biological products.<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"CISPLATIN for injection
\nfor intravenous use Initial U.S. Approval: 1978<\/h2>\nFacts about CISPLATIN for injection<\/h4>\n
\nProprietary Name: On Request
\nActive Ingredient(s): CISPLATIN for injection
\nDosage Forms And Strengths: Lyophilized powder: Single-dose vials containing 50 mg
\nCompany: WG Critical Care
\nCurrent indications: \u2022 Advanced testicular cancer \u2022 Advanced ovarian cancer \u2022 Advanced bladder cancer
\nMedicine Approved By: \u2013<\/strong>\u00a0European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a><\/p>\nAccess the best support services globally<\/h4>\n